Patents Examined by Timothy P Thomas
  • Patent number: 11001598
    Abstract: Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: May 11, 2021
    Assignee: AMGEN INC.
    Inventor: Brian S. Lucas
  • Patent number: 10994052
    Abstract: The present invention relates to the field of pharmaceutics and medicine, in particular, to a method for producing a suspended form of ground decellularized extracellular matrix with size-controlled structural components, the suspended form not 5 requiring pre-hydration, and to a product produced by this method, for stimulation of reparative regeneration of tissues.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: May 4, 2021
    Assignee: LIMITED LIABILITY COMPANY “NEARMEDIC PLUS”
    Inventors: Ashot Agabegovich Safoyan, Anatoly Petrovich Suslov, Vladimir Georgievich Nesterenko, Sergei Vladimirovich Nesterenko, Nina Vladimirovna Kalmykova, Ilya Alexandrovich Demyanenko, Oleg Vladimirovich Sorokin
  • Patent number: 10980811
    Abstract: Compounds, pharmaceutical compositions, and methods for reversing fosfomycin resistance are disclosed. Embodiments of the disclosed compounds inhibit fosfomycin-inhibiting enzymes. Some embodiments of the compounds are FosA inhibitors. The disclosed pharmaceutical compositions include (i) fosfomycin or a pharmaceutically acceptable salt thereof and (ii) a compound, or a pharmaceutically acceptable salt thereof, which inhibits a fosfomycin-inhibiting enzyme. A method of inhibiting growth of a fosfomycin-resistant bacterium includes contacting the bacterium with (i) fosfomycin or a pharmaceutically acceptable salt thereof and (ii) an effective amount of a disclosed compound or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: April 20, 2021
    Assignees: University of Pittsburgh—of the Commonwealth System of Higher Education, University of Maryland, Baltimore
    Inventors: Nicolas Paul Sluis-Cremer, Adam Daniel Tomich, Yohei Doi, Eric J. Sundberg, Erik H. Klontz, Steven Fletcher
  • Patent number: 10980808
    Abstract: The present invention relates to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to the use of novel classes of compounds, i.e. inhibitors of RSK (p90S6K); inhibitors of p70S6K; and inhibitors of rps6, to treat ribosomal disorders and ribosomopathies. In some embodiments, the invention relates to the use of specific Chk2 inhibitors and to the use of specific phenothiazine derivatives to treat ribosomal disorders and ribosomopathies, e.g. DBA.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: April 20, 2021
    Assignees: The Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: James Bradner, Jun Qi, Dennis Buckley, Leonard I. Zon, Elizabeth Macari
  • Patent number: 10968180
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: April 6, 2021
    Assignee: Regenacy Pharmaceuticals, LLC
    Inventors: John H. van Duzer, Ralph Mazitschek
  • Patent number: 10952966
    Abstract: A solid pharmaceutical composition comprising a solid dispersion of a BCS Class II drug in a solid carrier/hydrophilic carrier; and a pH modifier. The solid carrier/hydrophilic carrier has a melting point of between about 40° C. to about 60° C. and an HLB value of between about 10 and about 18. The BCS Class II drug may be telmisartan.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: March 23, 2021
    Assignee: Gattefosse India Pvt. Ltd.
    Inventors: Nabil Farah, Sunil Bambarkar, Vincent Jannin, Chhanda Kapadia, Mangal Nagarsenker, Meenakshi Venkataraman, Megha Marwah
  • Patent number: 10933064
    Abstract: This application relates to various crystalline forms of 5-bromo-2,6-di(1H-pyrazol-1-yl)pyrimidin-4-amine and salt thereof, as well as compositions and methods of using the same. In some embodiments the crystalline forms also contain water (“hydrates”). These materials are useful in the treatment of various diseases, including carcinomas, specifically lung cancer and more specifically non-small cell lung cancer.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: March 2, 2021
    Assignees: Novartis AG, Palobiofarma S.L.
    Inventors: Kai Cui, Julio Cesar Castro-Palomino Laria, Weiyong Kong
  • Patent number: 10906904
    Abstract: The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: February 2, 2021
    Assignee: HORIZON ORPHAN LLC
    Inventors: Todd C. Zankel, John Unitt, Timothy Phillips, Benoit Gourdet, Lorna Duffy
  • Patent number: 10898500
    Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib and acetylsalicylic acid, or a hydrate, solvate, metabolite or pharmaceutically acceptable salt thereof or a polymorph thereof for treating, preventing or managing diseases and conditions including hyperproliverative disorders such as cancer in humans and other mammals.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: January 26, 2021
    Assignees: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER AG
    Inventors: Olaf Weber, Karl Ziegelbauer
  • Patent number: 10888087
    Abstract: Compositions comprising lactams and non-ionic surfactants, suitable for use as antimicrobial, anti-biofilm and bacteriostatic compositions.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: January 12, 2021
    Assignee: Conopco, Inc.
    Inventor: Paul Damien Price
  • Patent number: 10882838
    Abstract: Disclosed are compounds and compositions that modulate cannabinoid receptors, methods of modulating cannabinoid receptors, and methods of treating various disorders related to the modulation of cannabinoid receptors. This disclosure is directed to methods of treating cannabinoid dependence, neuropathy, inflammation, glaucoma, a neurodegenerative disorder, a motor function disorder, a gastrointestinal disorder, hypothermia, emesis, loss of appetite, or anorexia associated with AIDS.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: January 5, 2021
    Assignee: NORTHEASTERN UNIVERSITY
    Inventors: Alexandros Makriyannis, Ganeshsingh A. Thakur, Rishi Sharma
  • Patent number: 10869859
    Abstract: The present invention relates to pharmacological interventions with pemafibrate for cardiovascular diseases and adverse cardiovascular events. In addition, the invention relates to the use of pemafibrate to treat dyslipidemia and type 2 diabetes mellitus and thereby reduce the risk of cardiovascular disease and adverse cardiovascular events.
    Type: Grant
    Filed: July 30, 2017
    Date of Patent: December 22, 2020
    Assignee: Kowa Company, Ltd.
    Inventors: Ryu Oshima, Gary Gordon
  • Patent number: 10869934
    Abstract: A compound capable of inhibiting cell proliferation, having a structure according to formula (I) wherein the variables in formula (I) are as defined in the specification. Such compounds are useful as anti-cancer agents, especially in antibody-drug conjugates.
    Type: Grant
    Filed: August 6, 2019
    Date of Patent: December 22, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ivar M. McDonald, Prasanna Sivaprakasam, Christiana I. Iwuagwu, Kevin M. Peese, Heng Cheng, Naidu S. Chowdari, Sanjeev Gangwar
  • Patent number: 10864198
    Abstract: The present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled LDL-C concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 diabetes mellitus with dyslipidemia in spite of intense statin use or well-controlled LDL-C.
    Type: Grant
    Filed: July 30, 2017
    Date of Patent: December 15, 2020
    Assignee: Kowa Company, Ltd.
    Inventors: Ryu Oshima, Gary Gordon
  • Patent number: 10857122
    Abstract: New uses of hypoestoxide, its derivatives and related compounds for treatment and prevention of neurodegenerative diseases (e.g. Parkinsons disease, Alzheimers disease, Huntingtons disease) are described. More specifically, the invention relates to methods for treating various neurodegenerative diseases through administration of hypoestoxide, its derivatives and related compounds, or a combination thereof to a subject with a neurodegenerative disease such that the symptoms of the disease are treated or at least partially alleviated. Furthermore, the present invention further provides methods of preventing the development of neurodegenerative diseases in individuals who are predisposed to developing a neurodegenerative disease over time.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: December 8, 2020
    Assignee: IMMUNE MODULATION, INC.
    Inventors: Howard Cottam, Emmanuel Ojo-Amaize, Emeka Nchekwube, Olusola Oyemade
  • Patent number: 10857234
    Abstract: The present disclosure relates to compositions and methods of carbonic anhydrase IX inhibitors. The present disclosure also relates to targeting conjugates of carbonic anhydrase IX inhibitors as therapeutics and imaging agents. The present disclosure also relates to the use of targeting conjugates of carbonic anhydrase IX inhibitors in imaging methods and cancer therapy.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: December 8, 2020
    Assignee: Endocyte Inc.
    Inventors: Christopher P. Leamon, Iontcho R. Vlahov, Jonathan M. Shillingford, Paul J. Kleindl
  • Patent number: 10850006
    Abstract: The present invention relates to protein biocoacervates and biomaterials and the methods of making and using protein biocoacervates and biomaterials. More specifically the present invention relates to protein biocoacervates and biomaterials that may be utilized for various medical applications including, but not limited to, drug delivery devices for the controlled release of pharmacologically active agents, coated medical devices (e.g. stents, valves . . . ), vessels, tubular grafts, vascular grafts, wound healing devices including protein suture biomaterials and biomeshes, dental plugs and implants, skin/bone/tissue grafts, tissue fillers, protein biomaterial adhesion prevention barriers, cell scaffolding and other biocompatible biocoacervate or biomaterial devices.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: December 1, 2020
    Assignee: PETVIVO HOLDINS, INC.
    Inventors: David B. Masters, Eric P. Berg
  • Patent number: 10836779
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: November 17, 2020
    Assignee: AMGEN INC.
    Inventors: Sean P. Brown, Yunxiao Li, Mike Elias Lizarzaburu, Brian S. Lucas, Nick A. Paras, Joshua Taygerly, Marc Vimolratana, Xianghong Wang, Ming Yu, Manuel Zancanella, Liusheng Zhu, Ana Gonzalez Buenrostro, Zhihong Li
  • Patent number: 10828277
    Abstract: Provided are an antioxidant complex for reducing the number of somatic cells in a livestock animal and a preparation method and application thereof. Active components of the preparation are melatonin (MT) having a centration of 2-30 g/L and vitamin C having a concentration of 1-14.3 g/L. The antioxidant complex provided in the present invention can effectively reduce the number of somatic cells in a diary cow and improve milk quality.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: November 10, 2020
    Assignee: China Agricultural University
    Inventor: Guoshi Liu
  • Patent number: 10815249
    Abstract: Provided are salts of (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine and various of crystal forms thereof, and compositions, medicaments, pharmaceutically acceptable formulations thereof, and methods of making same. In addition, provided are compounds comprising specific particle size distributions of crystalline (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine HCl and methods of making and modulating the particle size distributions.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: October 27, 2020
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Andrea Bauer, Xiaoxia Chen, Shahla Jamzad, Robert Joseph Prytko, Michael Joseph Sizensky, Haitao Zhang